[go: up one dir, main page]

PE20110147A1 - Composicion y proceso - 356 - Google Patents

Composicion y proceso - 356

Info

Publication number
PE20110147A1
PE20110147A1 PE2010001171A PE2010001171A PE20110147A1 PE 20110147 A1 PE20110147 A1 PE 20110147A1 PE 2010001171 A PE2010001171 A PE 2010001171A PE 2010001171 A PE2010001171 A PE 2010001171A PE 20110147 A1 PE20110147 A1 PE 20110147A1
Authority
PE
Peru
Prior art keywords
pyrimidin
salt
metoxybenzyl
metoxifenil
methylmorpholin
Prior art date
Application number
PE2010001171A
Other languages
English (en)
Inventor
Helen Blade
Gwydion Huw Churchill
Angela Charlotte Currie
Benjamin Charles Dobson
Peter Samuel Hynes
Martin Neal Kenworthy
Lyn Powel
Steven Anthony Raw
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PE20110147A1 publication Critical patent/PE20110147A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE A UN PROCESO PARA PREPARAR COMPUESTOS DERIVADOS DE (5-{2,4-bis[(3S)-3-METILMORFOLIN-4-IL]PIRIDO[2,3-d]PIRIMIDIN-7-IL}-2-METOXIFENIL)METANOL Y SUS SALES FOSFATO, SULFATO, MALATO, ENTRE OTROS; QUE COMPRENDE: A) REACCION DE UNA SAL DE 5-[(2E)-3-(DIMETILAMINO)PROP-2-ENOIL]-2-METOXIBENCILO DEL ACIDO PIVALICO O ESTER METILICO CON UN URACILO SUSTITUIDO EN LA POSICION 6 PARA OBTENER UNA SAL DE 5- (2,4-DIOXO-1,2,3,4-TETRAHIDROPIRIDO[2,3-d]PIRIMIDIN-7-IL)-2-METOXIBENCILO; B) REACCION DEL OBTENIDO CON UN AGENTE HALOGENANTE PARA OBTENER UNA SAL DE 5-(2,4-DIHALOPIRIDO[2,3-d]PIRIMIDIN-7-IL)-2-METOXIBENCILO; C) HACER REACCIONAR EL OBTENIDO CON METILMORFOLINA; D) ELIMINAR LOS GRUPOS PROTECTORES PARA OBTENER EL COMPUESTO (5-{2,4-bis[(3S)-3-METILMORFOLIN-4-IL]PIRIDO[2,3-d]PIRIMIDIN-7-IL}-2-METOXIFENIL)METANOL. ADICIONALMENTE SE PUEDE AISLAR EL COMPUESTO EN MENCION COMO UNA SAL. TAMBIEN REFIERE A UNA FORMULACION FARMACEUTICA. DICHO PROCESO ES UTIL PARA PREPARAR COMPUESTOS INHIBIDORES DE LA QUINASA mTOR UTIL EN EL TRATAMIENTO DE UNA ENFERMEDAD PROLIFERATIVA COMO EL CANCER
PE2010001171A 2008-06-20 2009-06-18 Composicion y proceso - 356 PE20110147A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7418808P 2008-06-20 2008-06-20
US15235009P 2009-02-13 2009-02-13

Publications (1)

Publication Number Publication Date
PE20110147A1 true PE20110147A1 (es) 2011-03-26

Family

ID=41051136

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2010001171A PE20110147A1 (es) 2008-06-20 2009-06-18 Composicion y proceso - 356

Country Status (26)

Country Link
US (1) US8198441B2 (es)
EP (1) EP2303875B1 (es)
JP (1) JP5607614B2 (es)
KR (1) KR101668497B1 (es)
CN (1) CN102137860B (es)
AR (1) AR072263A1 (es)
AU (1) AU2009261688B2 (es)
BR (1) BRPI0914912A2 (es)
CA (1) CA2728183C (es)
CL (1) CL2010001488A1 (es)
CO (1) CO6351729A2 (es)
CR (1) CR11859A (es)
DO (1) DOP2010000391A (es)
EA (1) EA019092B1 (es)
EC (1) ECSP10010696A (es)
ES (1) ES2398423T3 (es)
IL (1) IL210074A (es)
MX (1) MX2010014230A (es)
MY (1) MY172107A (es)
NI (1) NI201000225A (es)
PE (1) PE20110147A1 (es)
SV (1) SV2010003770A (es)
TW (1) TWI441821B (es)
UY (1) UY31917A (es)
WO (1) WO2009153597A2 (es)
ZA (1) ZA201101861B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0908100A2 (pt) * 2008-02-21 2015-10-06 Astrazeneca Ab produto combinação, uso de um composto, e, método de tratar câncer
AU2011343712B2 (en) 2010-12-16 2015-09-17 Genentech, Inc. Tricyclic PI3k inhibitor compounds and methods of use
CN104803922A (zh) * 2015-03-14 2015-07-29 长沙深橙生物科技有限公司 一种嘧啶衍生物的制备方法
CN106008559B (zh) * 2015-03-25 2020-10-16 中国科学院上海药物研究所 取代吡啶并嘧啶类化合物的合成工艺
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
US10596165B2 (en) 2018-02-12 2020-03-24 resTORbio, Inc. Combination therapies
WO2019180141A1 (en) 2018-03-23 2019-09-26 Bayer Aktiengesellschaft Combinations of rogaratinib
EP4302827A3 (en) 2018-06-15 2024-03-13 JANSSEN Pharmaceutica NV Rapamycin analogs and uses thereof
MX2022006807A (es) 2019-12-05 2022-09-12 Anakuria Therapeutics Inc Análogos de rapamicina y usos de estos.

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4560685A (en) 1984-06-18 1985-12-24 Dr. Karl Thomae Gesellschaft Mit Beschrankter Haftung 2-Piperazino-pteridines useful as antithrombotics and antimetastatics
DE3445298A1 (de) 1984-12-12 1986-06-12 Dr. Karl Thomae Gmbh, 7950 Biberach Neue pteridine, verfahren zu ihrer herstellung und deren verwendung als zwischenprodukte oder als arzneimittel
US5990117A (en) 1998-04-15 1999-11-23 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to quinazoline derivatives
PT1481970E (pt) 1999-09-07 2006-07-31 Syngenta Participations Ag Novos herbicidas
KR100774855B1 (ko) 2000-04-27 2007-11-08 아스텔라스세이야쿠 가부시키가이샤 축합 헤테로아릴 유도체
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
ES2518316T3 (es) 2002-12-06 2014-11-05 Debiopharm International Sa Compuestos heterocíclicos, métodos de fabricación de los mismos y su uso en terapia
ES2290743T3 (es) 2003-04-30 2008-02-16 The Institutes For Pharmaceutical Discovery, Llc Heteroarilos sustituidos como inhibidores de las proteina-tirosina fosfatasas.
GB0428475D0 (en) 2004-12-30 2005-02-02 4 Aza Bioscience Nv Pyrido(3,2-D)pyrimidine derivatives and pharmaceutical compositions useful as medicines for the treatment of autoimmune disorders
CA2612788A1 (en) 2005-06-24 2006-12-28 Steven Cesar Alfons De Jonghe Pyrido(3,2-d)pyrimidines and pharmaceutical compositions useful for treating hepatitis c
US20070128658A1 (en) * 2005-11-14 2007-06-07 Blackwell Helen E Fluorescent dyes, methods and uses thereof
WO2007060404A1 (en) * 2005-11-22 2007-05-31 Kudos Pharmaceuticals Limited PYRIDO-,PYRAZO- AND PYRIMIDO-PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
MY148688A (en) * 2006-08-23 2013-05-31 Kudos Pharm Ltd 2-methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mtor inhibitors
MX2010004074A (es) * 2007-10-15 2010-07-02 Astrazeneca Ab Combinacion 059.

Also Published As

Publication number Publication date
ECSP10010696A (es) 2011-01-31
KR20110027789A (ko) 2011-03-16
CN102137860A (zh) 2011-07-27
TWI441821B (zh) 2014-06-21
MX2010014230A (es) 2011-03-29
AR072263A1 (es) 2010-08-18
EP2303875A2 (en) 2011-04-06
ES2398423T3 (es) 2013-03-19
WO2009153597A2 (en) 2009-12-23
HK1155160A1 (en) 2012-05-11
EP2303875B1 (en) 2012-11-28
IL210074A (en) 2015-07-30
SV2010003770A (es) 2011-05-20
CR11859A (es) 2011-02-25
KR101668497B1 (ko) 2016-10-21
BRPI0914912A2 (pt) 2017-06-20
CN102137860B (zh) 2013-08-28
AU2009261688B2 (en) 2012-07-05
US20090318434A1 (en) 2009-12-24
CA2728183A1 (en) 2009-12-23
TW201012818A (en) 2010-04-01
AU2009261688A1 (en) 2009-12-23
CA2728183C (en) 2016-10-25
CL2010001488A1 (es) 2011-07-15
CO6351729A2 (es) 2011-12-20
JP5607614B2 (ja) 2014-10-15
ZA201101861B (en) 2011-11-30
US8198441B2 (en) 2012-06-12
WO2009153597A3 (en) 2010-05-06
EA201100063A1 (ru) 2011-10-31
UY31917A (es) 2010-01-29
NI201000225A (es) 2011-12-15
DOP2010000391A (es) 2011-01-15
MY172107A (en) 2019-11-14
EA019092B1 (ru) 2014-01-30
IL210074A0 (en) 2011-02-28
JP2011524889A (ja) 2011-09-08

Similar Documents

Publication Publication Date Title
PE20110147A1 (es) Composicion y proceso - 356
AU2014272774B2 (en) Imidazopyrrolidinone derivatives and their use in the treatment of disease
PE20121499A1 (es) Formas cristalinas de 3-(2, 6-dicloro-3, 5-dimetoxi-fenil)-1-{6-4[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas
IL278766B2 (en) Molecule, N-(3-chloro-1-(pyridin-3-yl)-H1-pyrazol-4-yl)-2-(methylsulfonyl)propanamide, for use in pest control
PE20191613A1 (es) Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret
CL2008002255A1 (es) Compuesto 3-({4-(2,2-difluoroetil)-3-(1h-pirrolo [2,3-b] piridin-5-il)-1h-pirazol-4-il] pirimidin-2-il}amino)propanonitrilo, inhibidor de raf; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del crecimiento celular anormal o cualquier enfermedad o afeccion mediada por raf.
BR112014014909A2 (pt) agonistas de tgr5 não sistêmicos
PE20100267A1 (es) Procedimiento para la preparacion de compuestos de aminocrotonilo
NZ605627A (en) Pyrrolo-pyrazine derivatives useful as inhibitors of atr kinase
TN2009000084A1 (en) Adenosine derivatives as a2a receptor agonists
PE20130386A1 (es) Derivados de indolizina, su procedimiento de preparacion y su aplicacion en terapeutica
BR122012012032B1 (pt) usos de inibidores de cinase úteis para preparação de composições farmacêuticas utilizáveis no tratamento de doenças proliferativas
NZ590179A (en) Fatty acid acetylated salicylates, diflunisal or triflusal and their uses
PE20190656A1 (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1
MA37405A1 (fr) Composés hétérocyclyle
HK1202541A1 (en) 2-amino, 6-phenyl substituted pyrido [2, 3 - d] pyrimidine derivatives useful as raf kinase inhibitors
BR112014030577B1 (pt) Dihidronaftiridinas e compostos relacionados, bem como composições farmacêuticas compreendendo os mesmos
AR071283A1 (es) Compuestos heterociclicos y usos de los mismos
MX2014001671A (es) Compuestos fungicidas de 1-{2-[2-halo-4-(4-halogen-fenoxi)-fenil]- 2-aluiniloxi-etil}-1h[1,2,4]triazol sustituidos.
PE20130236A1 (es) Composicion farmaceutica que comprende un derivado de amida o una sal farmaceuticamente aceptable del mismo
PH12015502802A1 (en) Formulation comprising a hypolipidemic agent
WO2012017239A3 (en) 4-(1h-indol-3-yl) -pyrimidines as alk inhibitors
MX2012007030A (es) Derivados de acido carboxilico de pirrolidina o tiazolidina, composicion farmaceutica y metodos para su uso en el tratamiento de transtornos metabolicos, como agonistas del receptor 43 acoplado por proteina-g (gpr43).
BR112013004662B8 (pt) Composto, composição farmacêutica, usos de um composto, e método para preparar uma composição farmacêutica
BR112014016635B8 (pt) composto, composição, e, uso de um composto

Legal Events

Date Code Title Description
FA Abandonment or withdrawal